Scroll Top

Interview with Don Bailey, CEO & President of Questcor Pharmaceuticals

[vc_video video_type=”vimeo” video_id=”41728854″]

Password: DBQust2

Questcor: Questcor Pharmaceuticals (NASDAQ: QCOR) is a biopharmaceutical company, formed in 1999 through a merger of RiboGene, Inc. and Cypros Pharmaceutical Corp., focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Their specific areas of focus are in the fields of neurology and nephrology and they are currently supporting research efforts in a variety of conditions having significant unmet medical need. Don Bailey, became CEO in 2006, the same year PAI made their initial investment in the relatively unknown California company. In 2007, Questcor invested in Acthar, which later was approved by FDA and is used for the treatment 19 different diseases.